多功能添加碳点,通过调节活性氧物种来抑制Aβ的聚合,并通过调节活性氧物种来去聚合Aβ纤维
Shenna Chen1, Ronghui Li1, Yanxu Liu1
1Hebei Technology Innovation Center for Energy Conversion Materials and Devices, College of Chemistry and Material Science, Hebei Normal University, Shijiazhuang 050024, P. R. China.
Langmuir : the ACS journal of surfaces and colloids
|November 27, 2024
概括
添加碳点 (N-CDs) 有效抑制β-粉样蛋白 (Aβ) 聚合,并分解Aβ纤维. 这项研究为阿尔茨海默氏症提供了一种新的治疗策略.
科学领域:
- 材料科学 材料科学 材料科学
- 生物化学 生物化学
- 神经科学是一个神经科学.
背景情况:
- 阿尔茨海默病 (AD) 的特点是,β-粉样蛋白 (Aβ) 聚成有毒纤维.
- 开发有效的治疗药物来抑制Aβ聚合和分解现有的纤维素对于AD治疗至关重要.
研究的目的:
- 为了合成和表征多功能添加碳点 (N-CDs).
- 研究N-CDs在抑制Aβ聚合和破坏预先形成的Aβ纤维的有效性.
- 阐明N-CD与Aβ和纤维素相互作用的机制.
主要方法:
- 使用各种光谱和显微技术合成和描述N-CD.
- 使用远紫外线圆形二极化 (CD) 光谱和传输电子显微镜 (TEM) 监测Aβ42的形状转换和形态学.
- 通过电子磁共振 (EPR) 谱学研究抑制和分解机制,以评估反应性氧物种 (ROS) 调制.
主要成果:
- 成功合成和表征N-CDs.
- N-CDs显示出Aβ42聚合的显著抑制和现有的Aβ42纤维的有效脱聚合.
- N-CDs调节ROS并与Aβ42纤维相互作用,在抑制聚合和减少纤维负荷方面发挥关键作用.
结论:
- 通过抑制Aβ42聚合和破坏Aβ42纤维,N-CDs显示出对阿尔茨海默病的治疗潜力.
- 这项研究为开发基于N-CD的阿尔茨海默病治疗策略提供了新的视角.
更多相关视频
09:52Modified Roller Tube Method for Precisely Localized and Repetitive Intermittent Imaging During Long-term Culture of Brain Slices in an Enclosed System
Published on: December 28, 2017
10.6K
08:53Characterization of pH-Dependent Reversible Self-Assembly of Amyloid Beta 1-40-Coated Gold Colloids
Published on: March 21, 2025
489
相关概念视频
Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
